50% off Premium Yearly

NYSE:PUK
Largest life insurer in the UK. Kind of a household name there. About half of its business is derived from Asia with the 2nd largest portion being from the US and a 3rd from the UK. This is a growth company, not a maximized dividend payout type, because the focus is on Asia. Good combination of defensiveness, cash generation and growth. The upside potential outweighs the downside risk.
Insurance company based in the UK. Have old legacy business, which is slow growing, as well as a business in the US plus a high growth business in Asia, which is insurance and wealth management. The Asian business is effectively the story. Strong balance sheet. 2.7% yield. There is a rumour that they may spin off the US asset which would create some big upside.
Prudential PLC is a American stock, trading under the symbol PUK (previously PUK-N on Stockchase) on the New York Stock Exchange (PUK). It is usually referred to as NYSE:PUK or PUK
In the last year, no analyst issued a Buy, Sell, or Hold rating on PUK (previously PUK-N on Stockchase) on Stockchase. Read the latest expert commentary for Prudential PLC.
Prudential PLC was recommended as a Top Pick by Darren Sissons on 2013-09-11. Read the latest stock experts ratings for Prudential PLC.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Prudential PLC.
Prudential PLC is followed by 28 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-15, Prudential PLC (PUK) stock closed at a price of $27.19.
It is cheap at 10X earnings, with a 3.04% dividend. Momentum is good, with a 34% YTD gain. It has only lost money once in the past decade, and decent (10%+) growth is predicted. Prudential is on track to achieve its 10% (or higher) growth target for new-business profit (NBP), gross operating free surplus generation (OFSG), operating profit after tax (OPAT) and dividend per share. NBP gains will be driven by further strength at its flagship HK unit, led by active-agents expansion and a product-mix improvement toward health and protection policies. The latter will also be promoted across other key markets, along with the repricing of medical policies to bolster profitability. The mainland China unit could see a recovery in the new-business margin on strong sales of participating policies, despite the downturn in bond yields which lowered investment-return assumption. Robust new-business and cost-improvement effort will support OFSG and OPAT, the bases for dividend gains. We think it looks fine, but keep our first line above in mind, please.
Unlock Premium - Try 5i Free